<!DOCTYPE html><html lang="en"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width,initial-scale=1"><title>Adrenergic and Cholinergic III - BHOLE</title><meta name="description" content="Indirect Adrenergic Mimicking drugsMAO Inhibitors - Phenelzine and SelegilineCOMT Inhibitors - Entacapone, Levodopa, CabidopaReuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, DextroamphetamineReuptake Inhibitors - DAT and NET: CocaineReuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)Releasing agent: Tyramine:Mixed Adrenergic Mimicking DrugsMethylphenidate /&hellip;"><meta name="generator" content="Publii Open-Source CMS for Static Site"><link rel="canonical" href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html"><link rel="alternate" type="application/atom+xml" href="https://BGASM.github.io/medNotes/feed.xml"><link rel="alternate" type="application/json" href="https://BGASM.github.io/medNotes/feed.json"><meta property="og:title" content="Adrenergic and Cholinergic III"><meta property="og:site_name" content="BHOLE"><meta property="og:description" content="Indirect Adrenergic Mimicking drugsMAO Inhibitors - Phenelzine and SelegilineCOMT Inhibitors - Entacapone, Levodopa, CabidopaReuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, DextroamphetamineReuptake Inhibitors - DAT and NET: CocaineReuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)Releasing agent: Tyramine:Mixed Adrenergic Mimicking DrugsMethylphenidate /&hellip;"><meta property="og:url" content="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html"><meta property="og:type" content="article"><link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin><link href="https://fonts.googleapis.com/css?family=Open+Sans:400,700|Roboto:400,700&amp;subset=latin-ext&amp;display=swap" rel="stylesheet"><style>:root{--body-font:'Open Sans',sans-serif;--heading-font:'Roboto',sans-serif;--logo-font:'Roboto',sans-serif;--menu-font:'Roboto',sans-serif}</style><link rel="stylesheet" href="https://BGASM.github.io/medNotes/assets/css/style.css?v=d2564d8d5f32cbb5488692bb93d80cc5"><script type="application/ld+json">{"@context":"http://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html"},"headline":"Adrenergic and Cholinergic III","datePublished":"2020-11-30T12:07","dateModified":"2020-12-06T17:03","description":"Indirect Adrenergic Mimicking drugsMAO Inhibitors - Phenelzine and SelegilineCOMT Inhibitors - Entacapone, Levodopa, CabidopaReuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, DextroamphetamineReuptake Inhibitors - DAT and NET: CocaineReuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)Releasing agent: Tyramine:Mixed Adrenergic Mimicking DrugsMethylphenidate /&hellip;","author":{"@type":"Person","name":"William Slattery"},"publisher":{"@type":"Organization","name":"William Slattery"}}</script></head><body><div class="site-container"><header class="top" id="js-header"><a class="logo" href="https://BGASM.github.io/medNotes/">BHOLE</a><nav class="navbar js-navbar"><button class="navbar__toggle js-toggle" aria-label="Menu" aria-haspopup="true" aria-expanded="false"><span class="navbar__toggle-box"><span class="navbar__toggle-inner">Menu</span></span></button><ul class="navbar__menu"><li><a href="https://github.com/BGASM" target="_self">My Github</a></li><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Fall 2020</span><ul class="navbar__submenu level-2" aria-hidden="true"><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Pharmacology</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html" target="_self">Adrenergic and Cholinergic I</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html" target="_self">Adrenergic and Cholinergic II</a></li><li class="active"><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html" target="_self">Adrenergic and Cholinergic III</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-inhibitors.html" target="_self">Adrenergic and Cholinergic IV</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html" target="_self">Adrenergic and Cholinergic V</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-i.html" target="_self">Chemotherapy I</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-ii.html" target="_self">Chemotherapy II</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">Pathophysiology</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html" target="_self">Edema Congestion and Hemostasis</a></li><li><a href="https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html" target="_self">Hemorrhage Thrombosis and Embolism</a></li><li><a href="https://BGASM.github.io/medNotes/infarction-shock-and-dic.html" target="_self">Infarction Shock and DIC</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">MMG</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/virology-i.html" target="_self">Virology I</a></li><li><a href="https://BGASM.github.io/medNotes/virology-ii.html" target="_self">Virology II</a></li><li><a href="https://BGASM.github.io/medNotes/virology-iii.html" target="_self">Virology III</a></li><li><a href="https://BGASM.github.io/medNotes/virology-v.html" target="_self">Virology V</a></li><li><a href="https://BGASM.github.io/medNotes/virology-vii.html" target="_self">Virology VII</a></li></ul></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">NMS</span><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/02-principles-of-neurobiology.html" target="_self">Principles of Neurobiology I</a></li><li><a href="https://BGASM.github.io/medNotes/nms03-principles-of-neurobiology-ii.html" target="_self">Principles of Neurobiology II</a></li></ul></li><li><span class="is-separator">Peds</span></li></ul></nav></header><main><article class="post"><div class="hero"><figure class="hero__image hero__image--overlay"><img src="https://BGASM.github.io/medNotes/media/website/Jul24_GettyImages-582759294_neurons-scaled.jpg" srcset="https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xs.jpg 300w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-sm.jpg 480w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-md.jpg 768w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-lg.jpg 1024w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xl.jpg 1360w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-2xl.jpg 1600w" sizes="(max-width: 1600px) 100vw, 1600px" loading="eager" alt=""></figure><header class="hero__content"><div class="wrapper"><div class="post__meta"><time datetime="2020-11-30T12:07">November 30, 2020</time></div><h1>Adrenergic and Cholinergic III</h1><div class="post__meta post__meta--author"><a href="https://BGASM.github.io/medNotes/authors/william-slattery/" class="feed__author invert">William Slattery</a></div></div></header></div><div class="wrapper post__entry"><ul><li><a href="#-indirect-adrenergic-mimicking-drugs">Indirect Adrenergic Mimicking drugs</a><ul><li><a href="#-mao-inhibitors---phenelzine-and-selegiline">MAO Inhibitors - Phenelzine and Selegiline</a></li><li><a href="#-comt-inhibitors---entacapone-levodopa-cabidopa">COMT Inhibitors - Entacapone, Levodopa, Cabidopa</a></li><li><a href="#-reuptake-inhibitors---net-amphetamine-methamphetamine-lisdexamphetamine-dextroamphetamine">Reuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, Dextroamphetamine</a></li><li><a href="#-reuptake-inhibitors---dat-and-net-cocaine">Reuptake Inhibitors - DAT and NET: Cocaine</a></li><li><a href="#-reuptake-inhibitors---net-and-5ht-imipramine-desipramine-amitriptyline-nortriptyline-tricyclic-antidepressants-tca">Reuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)</a></li><li><a href="#-releasing-agent-tyramine">Releasing agent: Tyramine:</a></li></ul></li><li><a href="#-mixed-adrenergic-mimicking-drugs">Mixed Adrenergic Mimicking Drugs</a><ul><li><a href="#---methylphenidate--dextroamphetamine">Methylphenidate / Dextroamphetamine</a></li><li><a href="#---pseudophedrin">Pseudophedrin</a><ul><li><a href="#summary-of-therapeutic-uses-of-indirect-and-mixed">Summary of Therapeutic Uses of Indirect and Mixed</a></li></ul></li></ul></li><li><a href="#notes">Notes</a><ul><li><a href="#questions-34353946474969">Questions: 34;35;39;46;47;49;69.</a><h3 id="indirect-adrenergic-mimicking-drugs">Indirect Adrenergic Mimicking drugs</h3></li></ul></li></ul><hr><ul><li>Enzyme inhbitors: MAO, COMT, DD (dopamine decarboxylase)<ul><li>MAO:<ul><li>Phenelzine</li><li>Selegiline</li></ul></li><li>COMT:<ul><li>Entacapone</li></ul></li><li>DD:<ul><li>Carbidopa</li></ul></li></ul></li><li>Uptake inhibitors: NET, DAT<ul><li>NET:<ul><li>Amphetamine</li><li>Methamphetamine</li></ul></li><li>DAT and NET:<ul><li>Cocaine</li><li>Methylphenidate</li></ul></li><li>NET and 5HT:<ul><li>Imipramine</li><li>Desipramine</li><li>Amitriptyline</li><li>Nortiptyline</li></ul></li></ul></li><li>Releasing agent:<ul><li>Tyramine: Not a drug, but does interfere.<h3 id="mao-inhibitors---phenelzine-and-selegiline">MAO Inhibitors - Phenelzine and Selegiline</h3></li></ul></li></ul><hr><ul><li>When catecholamines and 5HT are taken up, they are inactivated by MAO or COMPT. (Tissue more COMPT, Nerve ending more MAO)</li><li>This takes place before storage of NT. They get inactivated before storage.</li><li>MAO-A and MAO-B. Both cause irreversible inhibition of MAO.<ul><li>MAO-A is not selective</li><li>MAO-B is selevtive for dopamine.</li><li>Phenelzine inhibits MAO-A and MAO-B<ul><li>Increase in NE, DA, 5HT</li></ul></li><li>Selegiline inhibits MAO-B<ul><li>Increase in DA.</li></ul></li><li>Therapeutic Use:<ul><li>Depression: Phenelzine</li><li>Parkinson: Selegiline (disease with low levels of Dopa.)<h3 id="comt-inhibitors---entacapone-levodopa-cabidopa">COMT Inhibitors - Entacapone, Levodopa, Cabidopa</h3></li></ul></li></ul></li></ul><hr><ul><li>Dopamine is mostly made in CNS.<ul><li>If dopamine is not stored it can be inactivated by COMT</li><li>Dopamine is a norepi precursor. It cannot cross the BBB.<ul><li>This means that if there is degeneration of Dopamine production in the brain, peripheral Dopamine cannot rescue it because it cannot cross BBB.</li><li>L-DOPA can cross the BBB, but COMT and DD quickly degrade it.</li><li>Treatment revolves around inhibiting COMT and DD so that L-DOPA can cross the BBB.</li></ul></li></ul></li><li>Entacapone:<ul><li>Drug that inhibits COMT. This enhances the conversion of L-DOPA to DA.</li><li>No effect on DD, so efficacy is fairly low.</li><li>Drug has low CNS penetration, so it will not have effect on the brain.</li><li>We combine with Levodopa, which is not an inhibitor of any of these enzyme on its own.</li></ul></li><li>Levodopa:<ul><li>Not an enzyme inhibitor.</li><li>Levodopa enhances the effect of Entacapone.</li><li>Levodopa can cross the BBB.</li><li>It is similar (synthetic) to L-Dopa, so it saturates COMT and DD in the CNS.</li><li>This allows for more L-Dopa to cross BBB and get converted to DA.</li></ul></li><li>Carbidopa:<ul><li>DD inhibitor.</li><li>Unable to cross BBB.</li><li>Can be combined with Levodopa again.</li><li><strong>Carbidopa + Levodopa is the Gold Standard for Parkinsons Disease</strong><h3 id="reuptake-inhibitors---net-amphetamine-methamphetamine-lisdexamphetamine-dextroamphetamine">Reuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, Dextroamphetamine</h3></li></ul></li></ul><hr><ul><li><p>Amphetamine, Methamphetamine:</p><ul><li><p>Liposoluble, good bioavailability, long duration of action.</p></li><li><p>Penetrate the BBB</p></li><li><p>MoA is Inhibition of Norepinephrine Transporter - NET.</p><ul><li>Blocks uptake of Norepi, allowing it to accumulate in the synaptic cleft and continue its action.</li><li>Also enters nerve through NET and transports into vesicles through VMAT.</li><li>This causes Norepinephrine to displace out from the vesicle, where it can be released through reverse transport!</li></ul></li><li><p>Overall effect of NET inhibition is an ↑↑↑ of NE in the cleft, so an enhanced stimulant action.</p></li><li><p>Peripheral: B1 and A1 primarily</p><ul><li>Tachycardia (B1)</li><li>Vasoconstriction (A1)</li></ul></li><li><p>Therapeutic:</p><ul><li>Treat narcolepsy, ADHD, Binge eating</li></ul></li><li><p>Adverse:</p><ul><li>CNS stimuli: jitters, <strong>insomnia, anorexia</strong>, seizures, hallucination, paranoia.</li><li>PNS: headace, <strong>tachyarrhytmias, hypertension</strong>/hypotension, sweating, nausea, diarrhea,<h3 id="reuptake-inhibitors---dat-and-net-cocaine">Reuptake Inhibitors - DAT and NET: Cocaine</h3></li></ul></li></ul></li></ul><hr><ul><li>Cocaine:<ul><li>Penetrates BBB</li><li>MoA: DAT and NET inhibition. This increases the amount of both NE and DA in the synaptic cleft and therefore enhance the stimulant action of both.</li><li>In particular, it inhibits the reuptake in pleasure centers of CNS.<ul><li>Sympathomimetic effect in PNS. The reuptake is also blocked in PNS, but its less exciting.</li></ul></li><li>Therapeutic:<ul><li>Pretty limited. Only used as a local anesthetic.</li><li>No systemic effect. Only used topically (damn, not even orally)</li><li>Combine anesthetic and vasoconstriction (sympathomimetic)</li></ul></li><li>Adverse effects:<ul><li>Sudden death (<strong>cardiac and respiratory arrest</strong>).</li><li>Non-fatal effects: <strong>agitation, paranoia, tachycardia and hypertension</strong>, seizures, angina pectoris/myocardial ischemia, and hyperthermia.</li><li>Repeated “snorting” can result in chronic rhinitis, cartilaginous necrosis, sinusitis, and <strong>nose bleeds</strong>.<h3 id="reuptake-inhibitors---net-and-5ht-imipramine-desipramine-amitriptyline-nortriptyline-tricyclic-antidepressants-tca">Reuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)</h3></li></ul></li></ul></li></ul><hr><ul><li>Tricyclic Antidepressants (TCA)<ul><li>Inhibit the Norepinephrine transporter at pre-synaptic terminals in the CNS</li><li>Also inhibit the 5-HT transporters.</li><li>Both NE and 5HT accumulate in synaptic cleft, and mostly in CNS, so they stimulate the mood.</li><li>Therapeutic:<ul><li>Used to treat depression, peripheral neuropathy, and chronic pain.</li></ul></li><li>Additional Mechanism:<ul><li>Antagonist of serotonergic, A1, histamine, and muscarinic receptors.</li><li>These could potentially lead to adverse effects.</li></ul></li><li>Adverse Effects:<ul><li>CNS: Confusion and hallucinations (antimuscarininc)</li><li>Periphery:<ul><li>Postural hypotension (orthostatic) due to A1-adrenergic antagonism.</li><li>Atropine-like effects (antimuscarinic)</li><li>Sinus tachycardia, urinary retnetion, dry <strong>mouth</strong> (due to antimuscarinic).<h3 id="releasing-agent-tyramine">Releasing agent: Tyramine:</h3></li></ul></li></ul></li></ul></li></ul><hr><ul><li>Not a drug, but plays a role in drug interaction.<ul><li>Endogenous by-product of tyrosine metabolism. The amount of tyramine generated endogenously is not significant (only traces).</li><li>Found in high concentrations in some fermented foods (<strong>cheese, wine</strong>, etc..)</li><li>When foods containing tyramine are ingested, <strong>tyramine is inactivated (metabolized) by MAO in the liver and GI tract</strong> (rapid first-pass metabolism).<ul><li>Thus, normally, tyramine is not found in the systemic circulation.</li></ul></li></ul></li><li>Tyramine is not given to patients.<ul><li>In animals when administered the effect was enhancing imipramine and amyitriptyline because tyramine releases catecholamines from nerve endings.</li></ul></li><li>Route:<ul><li>Tyramine gets absorbed in the gut and then the blood and gets taken up by sypathetic nerve endings through NET.</li><li>Transported into vesicles by VMAT.</li><li>Displaces NE from vesicles.</li><li>Our patient is on MAO inhibitors, so there is no enzyme available to degrade the excess NE.</li></ul></li><li><strong>Can cause a hypertensive crisis.</strong></li></ul><h3 id="mixed-adrenergic-mimicking-drugs">Mixed Adrenergic Mimicking Drugs</h3><hr><ul><li>Direct and Indirect, they are mixed:<ul><li>Agonist on adrenergic causing release of NE and DA</li><li>Amphetamine-like Compounds</li><li>Methylphenidate / Dextroamphetamine: Schedule II</li><li>Pseudophedrin: Over the Counter<h3 id="--methylphenidate--dextroamphetamine">- Methylphenidate / Dextroamphetamine</h3></li></ul></li></ul><hr><ul><li>Structural analogs of amphetamine<ul><li>Mechanism: Indirectly <strong>inhibit DAT and NET</strong> as well as <strong>A1 agonist (vasoconstriction)</strong></li><li>Consequence is an increase in the amount of NE and DA in synaptic clefts (both periphery and CNS)</li><li>The NT’s are associated with learning and memory.</li></ul></li><li>Therapeutic:<ul><li>ADHD</li></ul></li><li>Adverse Effects:<ul><li>CNS: anorexia, dry mouth, anxiety, nausea, insomnia, agitation, irritability, dyskinesia, lethargy, dizziness, depression, emotional lability, confusion,</li><li>Periphery: abdominal pain, tachycardia (reflex bradycardia), blurred vision (A1 agonism) and bruxism<h3 id="--pseudophedrin">- Pseudophedrin</h3></li></ul></li></ul><hr><ul><li>Mechanism:<ul><li>Indirect: inhibits NET and release of NE from vesicles</li><li>Direct: A1 B1 agonist (low affinity for B2)</li></ul></li><li>Consequence:<ul><li>Inhibit NE reuptake and displaces NE from storage.</li><li>Increase accumulation of NE in periphery and CNS<ul><li>Similar to amphetamines, but less CNS stimulation.</li></ul></li></ul></li><li>Therapeutic:<ul><li>Nasal decongestant</li></ul></li><li>Adverse Effects:<ul><li>Atrial fibrillation, reflex bradycardia, ventricular permature beats, hypertension, insomnia.</li></ul></li></ul><h3 id="notes">Notes</h3><ul><li>Heteroreceptor<ul><li>Receptors that are stimulated by agents other than catecholamines</li></ul></li><li>Autoreceptor<ul><li>Respond to NT’s released from their own nerve ending.</li><li>Stimulation of these can inhibit further release</li><li>A2 most common autoreceptor. Inhibit catecholamine release.</li><li>B2 in pre-synaptic. Facilitates catecholamine release.</li><li>A lot more A2 than B2.</li></ul></li><li>Serotonin</li><li>Pathway of Tyrosine to Catecholamine:<ol><li>Tyrosine transported into the cell</li><li>Converted into L-dopa by Tyrosine Hydroxylase</li><li>L-Dopa converted to Dopamine by Dopa Decarboxylase DD</li><li>Dopamine can be converted into NorEpi by Dopamine Beta Hydrozylase</li><li>If not converted by DBH, then dopamine stored in vesicle by Vesicular Monoamine Transporter VMAT</li></ol></li></ul><h3 id="questions-34353946474969">Questions: 34;35;39;46;47;49;69.</h3></div><footer class="wrapper post__footer"><p class="post__last-updated">This article was updated on December 6, 2020</p></footer></article><nav class="post__nav"><div class="post__nav-inner"><div class="post__nav-prev"><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-prev"/></svg> <a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html" class="invert post__nav-link" rel="prev"><span>Previous</span> Adrenergic and Cholinergic I</a></div><div class="post__nav-next"><a href="https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html" class="invert post__nav-link" rel="next"><span>Next</span> PSL I Edema Congestion and Hemostasis </a><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-next"/></svg></div></div></nav></main><footer class="footer"><div class="footer__copyright"><p>Powered by <a href="https://getpublii.com" target="_blank" rel="nofollow noopener">Publii</a></p></div><button class="footer__bttop js-footer__bttop" aria-label="Back to top"><svg><title>Back to top</title><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#toparrow"/></svg></button></footer></div><script>window.publiiThemeMenuConfig = {    
        mobileMenuMode: 'overlay',
        animationSpeed: 300,
        submenuWidth: 'auto',
        doubleClickTime: 500,
        mobileMenuExpandableSubmenus: true, 
        relatedContainerForOverlayMenuSelector: '.top',
   };</script><script defer="defer" src="https://BGASM.github.io/medNotes/assets/js/scripts.min.js?v=f4c4d35432d0e17d212f2fae4e0f8247"></script><script>var images = document.querySelectorAll('img[loading]');

        for (var i = 0; i < images.length; i++) {
            if (images[i].complete) {
                images[i].classList.add('is-loaded');
            } else {
                images[i].addEventListener('load', function () {
                    this.classList.add('is-loaded');
                }, false);
            }
        }</script></body></html>